Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients With Hepatorenal Syndrome

NCT06256432 is registered in ClinicalTrials.gov with Noorik Biopharmaceuticals AG as lead sponsor.

NCT NCT06256432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06256432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Randomised, Open-Label, Phase II Study of Ambrisentan in Patients With Hepatorenal Syndrome
Lead sponsor
Noorik Biopharmaceuticals AG
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 17, 2024
Completion date
June 30, 2026
Enrollment
54 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, ascites hepatic, hepatorenal syndrome, liver cirrhosis